Nakul Singh1, Rahul Singh2, Randy Chris Bowen3, Mohamed H Abdel-Rahman4, Arun D Singh5. 1. Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA. 2. Department of Economics and Statistics and Data Science Center, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. 3. Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA. 4. Department of Ophthalmology and Visual Science, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA; Division of Human Genetics, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. 5. Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA. Electronic address: singha@ccf.org.
Abstract
PURPOSE: To estimate point prevalence of uveal melanoma in the patients with germline BAP1 pathogenic variant. DESIGN: Cohort study with risk assessment using Bayesian analysis. METHODS: The point prevalence estimate was obtained by Bayes's rule of reverse conditional probabilities. The probability of uveal melanoma given that BAP1 mutation exists was derived from the prevalence of uveal melanoma, prevalence of germline BAP1 pathogenic variants, and the probability of germline BAP1 pathogenic variant given that uveal melanoma is present. Confidence intervals (CIs) for each variable were calculated as the mean of Bernoulli random variables and for the risk estimate, by the delta method. The age at diagnosis and the gender of the uveal melanoma patients with BAP1 germline pathogenic variants obtained from previous publications or from authors' unpublished cohort was compared with those in the Surveillance, Epidemiology, and End Results (SEER) database. RESULTS: The point prevalence of uveal melanoma in patients with the germline BAP1 pathogenic variants in the US population was estimated to be 2.8% (95% CI, 0.88%-4.81%). In the SEER database, the median age at diagnosis of uveal melanomas was 63 (range 3-99 years) with a male-to-female ratio of 1.01:1. In comparison, uveal melanoma cases with BAP1 germline pathogenic variants from the US population (n = 27) had a median age at diagnosis of 50.5 years (range 16-71). CONCLUSIONS: Quantification of the risk of developing uveal melanoma can enhance counseling regarding surveillance in patients with germline BAP1 pathogenic variant.
PURPOSE: To estimate point prevalence of uveal melanoma in the patients with germline BAP1 pathogenic variant. DESIGN: Cohort study with risk assessment using Bayesian analysis. METHODS: The point prevalence estimate was obtained by Bayes's rule of reverse conditional probabilities. The probability of uveal melanoma given that BAP1 mutation exists was derived from the prevalence of uveal melanoma, prevalence of germline BAP1 pathogenic variants, and the probability of germline BAP1 pathogenic variant given that uveal melanoma is present. Confidence intervals (CIs) for each variable were calculated as the mean of Bernoulli random variables and for the risk estimate, by the delta method. The age at diagnosis and the gender of the uveal melanoma patients with BAP1 germline pathogenic variants obtained from previous publications or from authors' unpublished cohort was compared with those in the Surveillance, Epidemiology, and End Results (SEER) database. RESULTS: The point prevalence of uveal melanoma in patients with the germline BAP1 pathogenic variants in the US population was estimated to be 2.8% (95% CI, 0.88%-4.81%). In the SEER database, the median age at diagnosis of uveal melanomas was 63 (range 3-99 years) with a male-to-female ratio of 1.01:1. In comparison, uveal melanoma cases with BAP1 germline pathogenic variants from the US population (n = 27) had a median age at diagnosis of 50.5 years (range 16-71). CONCLUSIONS: Quantification of the risk of developing uveal melanoma can enhance counseling regarding surveillance in patients with germline BAP1 pathogenic variant.
Authors: Mrinali P Gupta; Anne Marie Lane; Margaret M DeAngelis; Katie Mayne; Margaux Crabtree; Evangelos S Gragoudas; Ivana K Kim Journal: JAMA Ophthalmol Date: 2015-08 Impact factor: 7.389
Authors: Lauren G Aoude; Claire M Vajdic; Anne Kricker; Bruce Armstrong; Nicholas K Hayward Journal: Pigment Cell Melanoma Res Date: 2012-12-11 Impact factor: 4.693
Authors: Alexandra M Haugh; Ching-Ni Njauw; Jeffrey A Bubley; Anna Elisa Verzì; Bin Zhang; Emily Kudalkar; Timothy VandenBoom; Kara Walton; Brian L Swick; Raj Kumar; Huma Q Rana; Sarah Cochrane; Shelley R McCormick; Christopher R Shea; Hensin Tsao; Pedram Gerami Journal: JAMA Dermatol Date: 2017-10-01 Impact factor: 10.282
Authors: Ching-Ni Jenny Njauw; Ivana Kim; Adriano Piris; Michele Gabree; Michael Taylor; Anne Marie Lane; Margaret M DeAngelis; Evangelos Gragoudas; Lyn M Duncan; Hensin Tsao Journal: PLoS One Date: 2012-04-24 Impact factor: 3.240
Authors: Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm Journal: Genet Med Date: 2015-03-05 Impact factor: 8.822